Recombinant chimeric horsepox virus (TNX-801) is attenuated relative to vaccinia virus strains in both in vitro and in vivo models
2024

Study of TNX-801 Vaccine Against Mpox and Smallpox

publication 10 minutes Evidence: high

Author Information

Author(s): Trefry Stephanie V., Awasthi Mayanka, Raney Christy N., Cregger Amy L., Gonzales Chase A., Layton Brittney L., Enamorado Robert N., Martinez Nelson A., Gohegan Deborah S., Masoud-Bahnamiri Masoudeh, Cho Jennifer Y., Myscofski Dawn M., Moulaei Tinoush, Ziółkowska Natasza E., Goebel Scott J., Lederman Seth, Bavari Sina, Nasar Farooq

Primary Institution: Discovery and Translations Sciences, Tonix Pharmaceuticals, Frederick, Maryland, USA

Hypothesis

Is TNX-801 more attenuated than older vaccinia virus strains in both in vitro and in vivo models?

Conclusion

TNX-801 is significantly more attenuated than older vaccinia virus strains, showing no disease in murine models.

Supporting Evidence

  • TNX-801 showed a small plaque phenotype in cell cultures.
  • TNX-801 had lower infectious titers compared to VACV strains.
  • TNX-801 did not cause disease in immunocompromised mice.

Takeaway

The TNX-801 vaccine is safer than older vaccines and doesn't make mice sick, which is good for people.

Methodology

The study involved in vitro and in vivo experiments comparing TNX-801 with various vaccinia virus strains.

Potential Biases

Potential bias due to the involvement of co-inventors in the study.

Limitations

The study is preclinical and results may not fully translate to human responses.

Participant Demographics

The study used murine models, specifically immunocompromised mice.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1128/msphere.00265-24

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication